Adsorption-based Separation and Recovery of Rare Earth Elements

Patel, Madhav; Karamalidis, Athanasios K.

doi:10.22541/essoar.168167398.84484841/v1

Cited by 1 publication

(1 citation statement)

References 296 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Following the production of the scandium isotopes, the recovery of the calcium, titanium, and vanadium target materials is a very important process, owing both to their high cost and their potential for use as stable long-term supply sources [ 40 ]. The separation of the target source from scandium usually involves several processes of selective precipitation, filtration, and washing, aimed at maximizing extraction and purification [ 124 , 125 , 126 , 127 , 128 ] ( Table 3 ). Different approaches have been used by various research teams in the course of these processes [ 129 , 130 , 131 , 132 ].…”

Section: Properties and Effects Of Scandium In The Context Of Nuclear...mentioning

confidence: 99%

Towards Clinical Development of Scandium Radioisotope Complexes for Use in Nuclear Medicine: Encouraging Prospects with the Chelator 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic Acid (DOTA) and Its Analogues

Ioannidis,

Lefkaritis,

Georgiades

et al. 2024

IJMS

View full text Add to dashboard Cite

Scandium (Sc) isotopes have recently attracted significant attention in the search for new radionuclides with potential uses in personalized medicine, especially in the treatment of specific cancer patient categories. In particular, Sc-43 and Sc-44, as positron emitters with a satisfactory half-life (3.9 and 4.0 h, respectively), are ideal for cancer diagnosis via Positron Emission Tomography (PET). On the other hand, Sc-47, as an emitter of beta particles and low gamma radiation, may be used as a therapeutic radionuclide, which also allows Single-Photon Emission Computed Tomography (SPECT) imaging. As these scandium isotopes follow the same biological pathway and chemical reactivity, they appear to fit perfectly into the “theranostic pair” concept. A step-by-step description, initiating from the moment of scandium isotope production and leading up to their preclinical and clinical trial applications, is presented. Recent developments related to the nuclear reactions selected and employed to produce the radionuclides Sc-43, Sc-44, and Sc-47, the chemical processing of these isotopes and the main target recovery methods are also included. Furthermore, the radiolabeling of the leading chelator, 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), and its structural analogues with scandium is also discussed and the advantages and disadvantages of scandium complexation are evaluated. Finally, a review of the preclinical studies and clinical trials involving scandium, as well as future challenges for its clinical uses and applications, are presented.

show abstract

Section: Properties and Effects Of Scandium In The Context Of Nuclear...mentioning

confidence: 99%

Towards Clinical Development of Scandium Radioisotope Complexes for Use in Nuclear Medicine: Encouraging Prospects with the Chelator 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic Acid (DOTA) and Its Analogues

Ioannidis,

Lefkaritis,

Georgiades

et al. 2024

IJMS

View full text Add to dashboard Cite

show abstract

Adsorption-based Separation and Recovery of Rare Earth Elements

Abstract: The separation of individual REEs increased with the use of complexing ligands as eluents for strongly acidic cation-exchanger (

Cited by 1 publication

References 296 publications

Towards Clinical Development of Scandium Radioisotope Complexes for Use in Nuclear Medicine: Encouraging Prospects with the Chelator 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic Acid (DOTA) and Its Analogues

Towards Clinical Development of Scandium Radioisotope Complexes for Use in Nuclear Medicine: Encouraging Prospects with the Chelator 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic Acid (DOTA) and Its Analogues

Contact Info

Product

Resources

About